“Abbott Vascular Int. (2011–2014), Amgen (2012–2018), AstraZeneca (2014–2017), Bayer (2013–2018), Boehringer Ingelheim (2013–2016), Boston Scientific (2010–2012), The Bristol Myers Squibb and Pfizer Alliance (2014–2016), The Alliance Daiichi Sankyo Europe GmbH and Eli Lilly and Company (2014–2017), Gedeon Richter Plc. (2014–2017), Menarini Int. Op. (2010–2012), MSD-Merck & Co. (2011–2014), Nova...

JILLIAN CORNISH, KAREN E. CALLON, JUERG A. GASSER, USHA BAVA, EDITH M. GARDINER, DAVID H. COY, GARTH J. S. COOPER, AND IAN R. REID Department of Medicine, School of Biological Sciences, University of Auckland, Auckland 1001, New Zealand; Bone Metabolism Unit, Novartis Pharma, Basel CH-4002, Switzerland; Garvan Institute, Sydney NSW 2010, Australia; and Peptide Research Laboratories, Tulane Univ...

The power of patient-centric events stems from the dialogue that takes place – dialogue with the power to effect positive change. This was particularly true of the second Chronic Obstructive Pulmonary Disease (COPD) Global Patient Leadership Summit [3] in Paris, as patients from around the world gathered to discuss the issues closest to the heart of the COPD community. For more information on C...

As tumors adapted, so did scientists. They resolved to combine targeted therapeutic agents into drug cocktails to control the evolution of resistance and thwart the persistent cancer cells, a strategy that’s finally coming to fruition. A slew of data from early-phase trials—presented by Novartis researchers and others at the American Society of Clinical Oncology (ASCO) meeting in June 2014—is t...

Acknowledgment: We wish to thanks Dr D.W. Cope for critical comments. This work was supported by the Fondation NRJ-Institut de France, the Wellcome Trust (grant 071436) and the Fondo de Investigaciones Sanitarias (grant 03/0177). D.R. is supported by the Ramón y Cajal program from MCYT, Spain. We wish to thank Novartis (Basel, Switzerland) for their gift of CGP 55845A and CGP 35348. Page 1 of 2...

Received for publication, June 8, 2005, and in revised form, November 3, 2005 Published, JBC Papers in Press, November 6, 2005, DOI 10.1074/jbc.C500241200 Yu Zhang, Benoit Gilquin, Saadi Khochbin, and Patrick Matthias From the Friedrich Miescher Institute for Biomedical Research, Novartis Research Foundation, P. O. Box 2543, Maulbeerstrasse 66, 4058 Basel, Switzerland and the INSERM U309, Insti...

Human African Trypanosomiasis Advait S. Nagle,† Shilpi Khare,† Arun Babu Kumar,‡ Frantisek Supek,† Andriy Buchynskyy,‡ Casey J. N. Mathison,† Naveen Kumar Chennamaneni,‡ Nagendar Pendem,‡ Frederick S. Buckner, Michael H. Gelb,‡,§ and Valentina Molteni*,† †Genomics Institute of the Novartis Research Foundation, 10675 John Jay Hopkins Drive, San Diego, California 92121, United States ‡Departments...

21 Carmen Jacobs, RN, OCN®, is a research nurse supervisor in the Gastrointestinal Medical Oncology Department at the University of Texas M.D. Anderson Cancer Center in Houston. Editorial assistance was provided by Meniscus Health Care Communications through an educational grant from Novartis Pharmaceuticals. Digital Object Identifier: 10.1188/09.CJON.21-23 Neuroendocrine Tumors A Rare Finding:...

1 Laboratory of NeuroPsychiatric Genetics, Biomedical Sciences Research Group, School of Medicine, Universidad Antonio Nariño, Bogotá, Colombia, 2 PhD Program in Health Sciences, School of Medicine, Universidad Antonio Nariño, Bogotá, Colombia, 3 Global Drug Development, Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, United States of America, 4 Department of Pharmacy, Universit...

Gastrointestinal stromal tumors (GISTs) are the most common sarcoma of the alimentary tract and are believed to derive from the interstitial Cell of Cajal. Imatinib mesylate (Gleevec; Novartis, Basel, Switzerland) has revolutionized the treatment of GISTs and is generally used in the metastatic and adjuvant settings. We report the case of a 61-year old man who was treated with neoadjuvant imati...